Itamar Raz
Impact in
- Endocrinology, Diabetes and Metabolism top 0.01%
- Diabetes Treatment and Management
- Diabetes Management and Research
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Nephrology top 0.1%
- Chronic Kidney Disease and Diabetes
Papers in
-
- Diabetes Treatment and Management 104
- Diabetes Management and Research 21
- Diabetes, Cardiovascular Risks, and Lipoproteins 17
- Growth Hormone and Insulin-like Growth Factors 9
- Nephrology 30
- Chronic Kidney Disease and Diabetes 29
- Co-authors
- Ofri Mosenzon (80 shared papers)Deepak L. Bhatt (70 shared papers)Darren K. McGuire (43 shared papers)Lawrence A. Leiter (45 shared papers)Stephen D. Wiviott (44 shared papers)Avivit Cahn (65 shared papers)Tomás Berl (7 shared papers)Edmund J. Lewis (7 shared papers)
- Journals
- Diabetes Care (58 papers)Diabetes/Metabolism Research and Reviews (26 papers)Diabetes Obesity and Metabolism (13 papers)Journal of the American College of Cardiology (12 papers)Circulation (12 papers)
- Partner nations
- IsraelUnited StatesCanada
In The Last Decade
Itamar Raz
403 papers receiving 34.6k citations
Itamar Raz's Hit Papers
Peers
Comparison fields: 5 of 135
- Endocrinology, Diabetes and Metabolism 12.6k
- Nephrology 4.0k
- Cardiology and Cardiovascular Medicine 4.3k
- Endocrine and Autonomic Systems 225
- Pharmaceutical Science 219
Countries citing papers authored by Itamar Raz
This map shows the geographic impact of Itamar Raz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Itamar Raz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Itamar Raz more than expected).
Fields of papers citing papers by Itamar Raz
This network shows the impact of papers produced by Itamar Raz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Itamar Raz. The network helps show where Itamar Raz may publish in the future.
Co-authors
The 25 scholars most cited alongside Itamar Raz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 415 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Hit paper breakdown → | 2018 | 4939 |
| 2 | Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes Hit paper breakdown → | 2001 | 4784 |
| 3 | Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Hit paper breakdown → | 2013 | 2834 |
| 4 | SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Hit paper breakdown → | 2018 | 2186 |
| 5 | Type 2 diabetes mellitus Hit paper breakdown → | 2015 | 1811 |
| 6 | Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary Hit paper breakdown → | 2007 | 1317 |
| 7 | Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Hit paper breakdown → | 2019 | 639 |
| 8 | Low ratio of fat to carbohydrate oxidation as predictor of weight gain: study of 24-h RQ Hit paper breakdown → | 1990 | 612 |
| 9 | Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial Hit paper breakdown → | 2014 | 610 |
| 10 | 2006 | 514 | |
| 11 | Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus Hit paper breakdown → | 2019 | 457 |
| 12 | 2006 | 441 | |
| 13 | 2001 | 418 | |
| 14 | Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Hit paper breakdown → | 2020 | 365 |
| 15 | 2003 | 324 | |
| 16 | 2017 | 306 | |
| 17 | 1991 | 288 | |
| 18 | 2009 | 269 | |
| 19 | Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Hit paper breakdown → | 2019 | 266 |
| 20 | 2005 | 257 |
About Itamar Raz
Itamar Raz is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology, Cardiology and Cardiovascular Medicine, Genetics and Physiology, having authored 415 papers that have together received 36.8k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (104 papers), Chronic Kidney Disease and Diabetes (29 papers), Diabetes Management and Research (21 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (17 papers), Diabetes and associated disorders (12 papers), Blood Pressure and Hypertension Studies (10 papers), Growth Hormone and Insulin-like Growth Factors (9 papers) and Pancreatic function and diabetes (7 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (12.6k citations), Nephrology (4.0k citations), Cardiology and Cardiovascular Medicine (4.3k citations), Endocrine and Autonomic Systems (225 citations) and Pharmaceutical Science (219 citations). Itamar Raz has collaborated with scholars based in Israel, United States and Canada. Frequent co-authors include Ofri Mosenzon, Deepak L. Bhatt, Darren K. McGuire, Lawrence A. Leiter, Stephen D. Wiviott, Avivit Cahn, Tomás Berl, Edmund J. Lewis, Julia Breyer Lewis and Lawrence G. Hunsicker. Their work appears in journals such as Diabetes Care, Diabetes/Metabolism Research and Reviews, Diabetes Obesity and Metabolism, Journal of the American College of Cardiology and Circulation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.